Dalvance

Staphylococcus Epidermidis SEM

Iterum Therapeutics Ltd., Raised $40 Million in Series A For Licensure and Development of Anti-Infective Drug

Iterum Therapeutics Ltd. secured $40 million in Series A funding led by Frazier Healthcare Partners together with other venture capitalists. The said fund will be used to acquire license and to enhance the development of the anti-infective drug that could counter certain bacteria's resistance to antibiotic.

Read Full Article

Subscribe to VCpost newsletter

Sign up for our Deals of the Day newsletter.
We will not spam you!

Real Time Analytics